Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Published in: -
Access to document
10.1182/bloodadvances.2022009578
document
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the...
Jaap A. van Doesum, Jon Salmanton-García, Francesco Marchesi, Roberta Di Blasi, Iker Falces-Romero, Alba Cabirta, Francesca Farina, Caroline Besson, Barbora Weinbergerová, Jens Van Praet, Martin Schönlein, Alberto López-García, Sylvain Lamure, Anna Guidetti, Cristina De Ramón-Sánchez, Josip Batinić, Eleni Gavriilaki, Athanasios Tragiannidis, Maria Chiara Tisi, Gaëtan PlantefeveVerena Petzer, Irati Ormazabal-Vélez, Joyce Marques de Almeida, Monia Marchetti, Johan Maertens, Marina Machado, Austin Kulasekararaj, José Ángel Hernández-Rivas, Maria Gomes da Silva, Noemí Fernández, Ildefonso Espigado, Ľuboš Drgoňa, Giulia Dragonetti, Elisabetta Metafuni, Maria Calbacho, Ola Blennow, Dominik Wolf, Bjorn van Anrooij, Raquel Nunes Rodrigues, Anna Nordlander, Juan Alberto Martín-González, Raphaël Liévin, Moraima Jiménez, Stefanie K. Gräfe, Ramón García-Sanz, Raúl Córdoba, Laman Rahimli, Tom van Meerten, Oliver A. Cornely, Livio Pagano
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Published in: Clinical Cancer Research
Access to document
10.1158/1078-0432.CCR-22-3136
document
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7. Patients and Methods: Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous antiCD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2-3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival...
Jason R. Westin, Frederick L. Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B. Miklos, Matthew L. Ulrickson, Miguel Angel Perales, Umar Farooq, Luciano Wannesson, Lori Leslie, Marie José Kersten, Caron A. Jacobson, John M. Pagel, Gerald Wulf, Patrick Johnston, Aaron P. Rapoport, Linqiu Du, Saran VardhanabhutiSimone Filosto, Jina Shah, Julia T. Snider, Paul Cheng, Christina To, Olalekan O. Oluwole, A. Sureda
MO-0960 Evaluating semi-automated 18F-FDG PET segmentation methods to predict Large B-cell lymphoma outcomes
Published in: Radiotherapy and Oncology
Access to document
10.1016/s0167-8140(23)08500-6
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
Published in: JCO oncology practice
Access to document
10.1200/OP.22.00501
document
PURPOSE:Prompt recognition of acute chimeric antigen receptor T (CAR T)-cell-mediated toxicities is crucial because adequate and timely management can prevent or reverse potential life-threatening complications. In the outpatient setting, patients and informal caregivers have to recognize and report signs and symptoms marking these acute toxicities. This study provides a core set of patient- and caregiver-reported signs and symptoms (outcomes, P/CROs) and definitions of red flags warranting immediate action to include in a daily checklist for support at home, with the goal to make outpatient post-CAR T-cell care safer,...
Anne M. Spanjaart, Elise R.A. Pennings, Milan Kos, Pim G.N.J. Mutsaers, Pieternella J. Lugtenburg, Tom Van Meerten, Jaap A. Van Doesum, Monique C. Minnema, Margot Jak, Suzanne Van Dorp, Joost S.P. Vermaat, Marjolein W.M. Van Der Poel, Martijn G.H. Van Oijen, Maria T. Kuipers, Inger S. Nijhof, Marie José Kersten
High frequency of hyperglycaemia observed during CAR T-cell treatment
Published in: Diabetic Medicine
Access to document
10.1111/dme.14969
document